NCT07036289Active, not recruiting
Periodontitis Treatment and Heart Failure
Effects Of PeriodontitisTtreatment On The Worsening Of Heart Failure: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
Heart failure (HF) is a rapidly growing public health issue affecting more than 40 million individuals globally; while gum disease with bone loss affects 50% of people in general. The objective of this study is to evaluate the effect of dental treatment on blood levels of a HF parameter at 3 and at 6 months. In addition to verify the relation between blood and salivary exam results and severity of HF. Imune response against one important oral bacterial will be also monitored at 3 and 6 months. Approximately 80 adult individuals will be included and divided into 3 groups. The first two groups will receive dental scaling and root planing (periodontitis individuals with heart failure \[n = 25\]; periodontitis individuals without heart failure \[n = 25\]). The third group named negative control will receive dental treatment only after 6 months of dental follow-up (periodontitis individuals with heart failure \[n = 25\]). HF treatment by oral medication will be continuous. Blood, salivary, microbiological and immune examinations will be performed in addition to the periodontal treatment of scaling and root planning. Clinical data will be obtained both for initial diagnosis and disease staging and for longitudinal follow-up.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 14 Jun 2025
- Start date
- Jun 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- University of Taubate
- Diseases
- Heart failure
- NCT number
- NCT07036289
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From Jun 2025 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- individuals with stage D of HF using vasoactive drugs or circulatory devices;
- drugs and cardiotoxic substances such as cocaine and oncological chemotherapy;
Other illness
- participants who do not meet the criteria for periodontal disease;
- diabetes, obesity, chronic kidney disease and other non-ischemic causes of HF;
- familial and congenital heart alterations and myocarditis
- rheumatological and autoimmune diseases;
Lab values
- HF individuals with preserved ejection fraction;
Other
- pregnant or lactating women;
- participants who are unable to comply with the study protocol;
- Specifically for the negative control group a progression of periodontitis revealed by 0.3mm additional clinical attachment loss within 6 months of follow-up.
Who the study is looking for
- minimum of 35 years of age;
- possibility and availability for medical and dental examinations;
- specifically for HF groups: HF having as primary causes ischemic problems, myocardial infarction, hypertension and valvulopathies will be selected
- HF with intermediate or reduced ejection fraction under one of the three following pharmacological therapeutic regimens: a) Angiotensin Converting Enzyme Inhibitors, as the first option, or b) Angiotensin II Receptor Blockers and b) Angiotensin II Receptor Blockers and c) Angiotensin/neprilysin receptor inhibitors.
Age in the registry: 35 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Taubate Dental School Coordinator of this site? Confirm its status | Taubaté | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.